北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (4): 607-609. doi: 10.19723/j.issn.1671-167X.2020.04.001
• 专家笔谈 • 下一篇
雄激素剥夺治疗相关心血管疾病的机制与临床对策
徐涛1,△(
),韩敬丽1,姚伟娟2
- 1.北京大学人民医院泌尿外科,北京 100044
2.北京大学基础医学院生理学与病理生理学系,北京 100191
中图分类号:
- R697+.3
| [1] |
Gupta D, Lee Chuy K, Yang J C, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer[J]. J Oncol Pract, 2018,14(10):580-587.
pmid: 30312560 |
| [2] |
Farrell SO, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer[J]. J Clin Oncol, 2015,33(11):1243-1251.
pmid: 25732167 |
| [3] |
Conteduca V, Lorenzo GD, Tartarone A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy[J]. Crit Rev Oncol Hematol, 2013,86(1):42-51.
doi: 10.1016/j.critrevonc.2012.09.008 pmid: 23092636 |
| [4] | Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer[J]. J Clin Oncol, 2006,24(27):4448-4456. |
| [5] |
Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction[J]. JAMA, 2009,302(8):866-873.
doi: 10.1001/jama.2009.1137 pmid: 19706860 |
| [6] |
Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer[J]. J Natl Cancer Inst, 2010,102(1):39-46.
pmid: 19996060 |
| [7] |
Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: A meta-analysis of population-based observational studies[J]. PLoS One, 2014,9(9):e107516.
doi: 10.1371/journal.pone.0107516 pmid: 25264674 |
| [8] | Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis[J]. Eur Urol, 2015,68(3):386-396. |
| [9] | Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: A meta-analysis and systematic review[J]. BMC Cancer, 2016,16(1):180. |
| [10] | Elagizi A, Köhler TS, Lavie CJ. Testosterone and cardiovascular health[J]. Mayo Clin Proc, 2018,93(1):83-100. |
| [11] |
Clinton TN, Woldu SL, Raj GV. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer[J]. Expert Opin Pharmacother, 2017,18(8):825-832.
doi: 10.1080/14656566.2017.1328056 pmid: 28480768 |
| [12] |
Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist[J]. Eur Urol, 2014,65(3):565-573.
pmid: 24210090 |
| [13] |
Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease[J]. J Urol, 2019,202(6):1199-1208.
pmid: 31188734 |
| [14] | A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease(PRONOUNCE)[Z/OL]. (2016-01-26)[2020-04-06]. https://clinicaltrials.gov/ct2/show/NCT02663908?term=NCT02663908&draw=2&rank=1. |
| [15] | Cone EB, Marchese M, Reese S, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists[J/OL]. BJU Int, 3(2020-03-30)[2020-04-10]. https://pubmed.ncbi.nlm.nih.gov/32232935/?from_single_result=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists&expanded_search_query=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists. |
| [16] | Bubley GJ. Is the flare phenomenon clinically significant?[J]. Urology, 2001,58(2):5-9. |
| [17] | Knutsson A, Hsiung S, Celik S, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE-/- mice[J]. Sci Rep, 2016,6(1):26220. |
| [18] | Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis[J]. J Lipid Res, 2009,50(Suppl):352-357. |
| [19] |
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase Ⅲ study in patients with prostate cancer[J]. BJU Int, 2008,102(11):1531-1538.
pmid: 19035858 |
| [20] |
Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?[J]. Ther Adv Urol, 2016,8(2):118-129.
doi: 10.1177/1756287215617872 |
| [21] | Wang Q, Zhou J, Yao W, et al. Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation[J]. Eur Urol, 2019,18(Suppl 1):e72. |
| [22] |
Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer[J]. Circulation, 2016,133(5):537-541.
pmid: 26831435 |
| [1] | 黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报（医学版）, 2024, 56(4): 557-561. |
| [2] | 邢念增,王明帅,杨飞亚,尹路,韩苏军. 前列腺免活检创新理念的临床实践及其应用前景[J]. 北京大学学报（医学版）, 2024, 56(4): 565-566. |
| [3] | 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报（医学版）, 2024, 56(4): 589-593. |
| [4] | 于书慧,韩佳凝,钟丽君,陈聪语,肖云翔,黄燕波,杨洋,车新艳. 术前盆底肌电生理参数对前列腺癌根治性切除术后早期尿失禁的预测价值[J]. 北京大学学报（医学版）, 2024, 56(4): 594-599. |
| [5] | 和静,房中则,杨颖,刘静,马文瑶,霍勇,高炜,武阳丰,谢高强. 血浆中脂质代谢分子与颈动脉粥样硬化斑块、传统心血管危险因素及膳食因素的关系[J]. 北京大学学报（医学版）, 2024, 56(4): 722-728. |
| [6] | 陈楚云,孙蓬飞,赵静,贾佳,范芳芳,王春燕,李建平,姜一梦,霍勇,张岩. 北京社区人群促红细胞生成素相关因素及其与10年心血管疾病风险的关系[J]. 北京大学学报（医学版）, 2023, 55(6): 1068-1073. |
| [7] | 刘颖,霍然,徐慧敏,王筝,王涛,袁慧书. 磁共振血管壁成像评估颈动脉中重度狭窄患者斑块特征与脑血流灌注的相关性[J]. 北京大学学报（医学版）, 2023, 55(4): 646-651. |
| [8] | 张紫薇,花语蒙,刘爱萍. 中国中老年人群抑郁症状、缺血性心血管疾病10年风险对心血管疾病的联合影响[J]. 北京大学学报（医学版）, 2023, 55(3): 465-470. |
| [9] | 张云静,乔丽颖,祁萌,严颖,亢伟伟,刘国臻,王明远,席云峰,王胜锋. 乳腺癌患者新发心血管疾病预测模型的建立与验证：基于内蒙古区域医疗数据[J]. 北京大学学报（医学版）, 2023, 55(3): 471-479. |
| [10] | 张明露,刘秋萍,巩超,王佳敏,周恬静,刘晓非,沈鹏,林鸿波,唐迅,高培. 阿司匹林用于心血管病一级预防的不同策略比较：一项马尔可夫模型研究[J]. 北京大学学报（医学版）, 2023, 55(3): 480-487. |
| [11] | 董尔丹. 心血管受体的信号转导与疾病[J]. 北京大学学报（医学版）, 2022, 54(5): 796-802. |
| [12] | 刘圣杰,侯惠民,吕政通,丁鑫,王璐,张磊,刘明. 双极雄激素序贯免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌4例[J]. 北京大学学报（医学版）, 2022, 54(4): 766-769. |
| [13] | 白杲琛,宋毅,金杰,虞巍,何志嵩. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床疗效[J]. 北京大学学报（医学版）, 2021, 53(4): 686-691. |
| [14] | 郭子宁, 梁志生, 周仪, 张娜, 黄捷. 基于国际疾病分类的心血管疾病亚型的基因组学研究[J]. 北京大学学报（医学版）, 2021, 53(3): 453-459. |
| [15] | 刘秋萍,陈汐瑾,王佳敏,刘晓非,司亚琴,梁靖媛,沈鹏,林鸿波,唐迅,高培. 基于马尔可夫模型的社区人群心血管病筛查策略的效果评价[J]. 北京大学学报（医学版）, 2021, 53(3): 460-466. |
|
||
